Hanmi Pharmaceutical has signed an exclusive distribution agreement with Laboratorios Sanfer, Mexico’s largest privately held pharmaceutical firm, for the commercialization of efpeglenatide, the South Korea–based company’s GLP-1 receptor agonist for obesity and metabolic diseases. The deal also covers the Dapalon Family, Hanmi’s proprietary oral diabetes treatment portfolio. Sanfer will lead regulatory approvals, marketing, and commercial deployment across Mexico—a country where obesity affects nearly 37 percent of the population and diabetes prevalence exceeds 16 percent.

What this deal reveals about regional demand for GLP-1 and metabolic drugs beyond U.S. and EU markets

The Hanmi–Sanfer partnership confirms that Latin America is emerging as a second-wave battleground for GLP-1 therapies as supply bottlenecks and pricing pressure limit short-term penetration in traditional markets. Mexico, with its dual burden of obesity and diabetes and a healthcare system under cost strain, presents both a challenge and an opportunity. Unlike the U.S., where payor coverage and telehealth channels drive demand, the Mexican market demands pricing flexibility, local regulatory alignment, and decentralized distribution infrastructure.

Hanmi’s decision to bundle efpeglenatide with the Dapalon franchise reflects a pragmatic bet on integrated metabolic care. While GLP-1 therapies have generated widespread interest globally—led by semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly)—there is growing appetite for combination therapies that can address glycemic control alongside weight loss, especially in markets where out-of-pocket healthcare spending remains high. In Mexico, where nearly 35 percent of household healthcare expenditures are borne by individuals, affordability and formulation versatility will likely dictate uptake far more than brand recognition or prescriber influence alone.

Sanfer’s recent acquisition of Probiomed, which bolsters its biologics manufacturing and LATAM distribution footprint, gives Hanmi a more seasoned partner than typical regional distributors. For Hanmi, this marks a notable shift from its earlier strategy of targeting the U.S. and Chinese markets through direct out-licensing. It also comes amid the company’s effort to reposition efpeglenatide, initially out-licensed to Sanofi before being returned, as a scalable alternative to more expensive injectable GLP-1s.

Why the regulatory and trial timelines signal a staged market entry strategy

While the distribution deal has been announced, efpeglenatide is still pending approval in its home market of South Korea. Hanmi filed for obesity treatment approval with the Ministry of Food and Drug Safety in December 2025, and a separate Phase 3 IND for a combination therapy study involving metformin and SGLT-2 inhibitors was approved just days ago in January 2026.

This sequencing suggests Hanmi is pursuing a multi-pronged clinical development strategy aimed at broadening both indications and geographies in parallel, rather than waiting for full commercialization in any one market. The initial focus on obesity, followed by planned diabetes indications in 2028, mirrors Novo Nordisk’s lifecycle strategy for semaglutide—though Hanmi will face significant competitive friction as GLP-1 class expansion accelerates globally.

Critically, Mexican regulatory timelines may be shorter and more navigable compared to markets like the United States or Japan, particularly for chronic conditions with high national disease burden. By securing an experienced partner in Sanfer, Hanmi may be positioning efpeglenatide as a medium-term challenger in public tenders or social security formularies, assuming clinical trial readouts are favorable.

What this means for other Asian biopharmas seeking market share in Latin America

The deal signals a potentially underexplored commercial pathway for Asian drug developers, especially those with mid-stage pipelines and limited Western commercialization capacity. Hanmi’s pivot to Latin America could be interpreted as an adaptive response to post-COVID disruptions in global regulatory harmonization, geopolitical friction, and licensing volatility.

In contrast to the well-trodden path of U.S. FDA or European Medicines Agency submissions, LATAM markets offer route-to-market diversity for companies that can tolerate regional pricing variability and slower scale. Mexico’s inclusion in several regional procurement mechanisms, including PAHO and UNOPS frameworks, may further ease entry barriers if Hanmi pursues regional labeling or public sector contracts later in the decade.

Industry observers also note that Sanfer’s vertical integration and cross-border footprint in the United States could serve as a bridgehead if Hanmi revisits North American ambitions. While efpeglenatide may not directly compete against Wegovy or Mounjaro in the U.S. commercial obesity segment, its differentiated formulation or cost advantages may offer utility in Medicaid populations or underserved metabolic disease cohorts.

What risks remain around manufacturing, regulatory review, and long-term differentiation

Hanmi’s supply commitment to Sanfer implies manufacturing readiness at commercial scale, though it is unclear whether the company has secured secondary sourcing or fill–finish redundancy to support regional volume. Any delay in South Korean regulatory approvals or clinical readouts from the newly authorized Phase 3 trial could disrupt the planned rollout timeline in Mexico, particularly if local authorities require bridging data or post-market surveillance alignment.

Clinicians tracking GLP-1 expansion caution that efpeglenatide must demonstrate real-world differentiation, especially given its delayed entry compared to first-movers. Without clear superiority in efficacy, tolerability, or dosing frequency, Hanmi may face pressure to price aggressively—a strategy that could constrain long-term margins if local volume uptake does not meet expectations.

Reimbursement dynamics in Mexico also remain a potential obstacle. While Sanfer’s local expertise may ease market entry, the fragmented payer environment and slow uptake of new biologics in public health channels could limit near-term visibility.

What to watch in 2026 and beyond as Hanmi’s GLP-1 ambitions evolve

The second half of 2026 will be pivotal for Hanmi. If efpeglenatide gains regulatory approval for obesity in South Korea, and early traction emerges in Mexico, the company may accelerate filings in other mid-tier LATAM markets like Colombia, Peru, and Argentina. A broader diabetes indication by 2028 would expand the total addressable market, but only if pricing, manufacturing, and clinical positioning align with regional payer expectations.

Hanmi’s deeper pipeline moves, such as exploring co-formulations or oral GLP-1 analogs, could offer additional optionality. However, much depends on how the broader GLP-1 narrative evolves globally—particularly whether supply constraints ease, competitors like Pfizer and Amgen gain late-stage traction, and whether pricing erosion accelerates in saturated markets.

For now, the Sanfer partnership offers Hanmi a credible path to commercial proof-of-concept in a high-need, fast-growing region—and could become a case study for how Asian biotechs can carve global market share outside the traditional U.S.–EU axis.

  Dapalon Family, diabetes treatment, efpeglenatide, GLP-1, Hanmi Pharmaceutical, Laboratorios Sanfer, Latin America pharma, Mexican healthcare, obesity treatment